Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2020]
|
| In: |
Quality of life research
Year: 2019, Volume: 29, Issue: 1, Pages: 69-79 |
| ISSN: | 1573-2649 |
| DOI: | 10.1007/s11136-019-02307-5 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11136-019-02307-5
|
| Author Notes: | Katja Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda, Hartmut Goldschmidt |
| Summary: | Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted. |
|---|---|
| Item Description: | Published online: 24 September 2019 Gesehen am 14.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1573-2649 |
| DOI: | 10.1007/s11136-019-02307-5 |